In recent years, the FDA has demonstrated a too-cozy relationship with the pharmaceutical industry and an attitude of shielding rather than disclosing information. Now is the time to reform the FDA's culture and reassert that the agency's top priority is what's good for John Q. Public when it comes to reviewing drugs in the marketplace and making new miracle medicines available.One of those anti-corporate liberal Democrats, you ask? Nope.
I wonder about the relationship between Crawford's resignation last Friday, and the resignation of Susan F. Wood, three weeks earlier in exasperation over the FDA's decision to further delay a ruling on whether the morning after pill should be made more easily accessible. Her comment at the time:
I can no longer serve as staff when scientific and clinical evidence, fully evaluated and recommended for approval by the professional staff here, has been overruled.When I was a boy in school in the sixties, in the conservative South, my interest in science was universally regarded as a good thing. Do parents these days pray that their youngsters won't be corrupted by their secularist science teachers?
Does Wood now regret her resignation? Did hers in some way contribute to Crawford's decision last week? Anybody have the "inside dope" at the FDA?
No comments:
Post a Comment